| Literature DB >> 31121838 |
Onur M Yaman1, Ibrahim Guner2, Gulcan Guntas3, Osman Fuat Sonmez4, Gamze Tanriverdi5, Aris Cakiris6, Ugur Aksu7, Sibel Akyol8, Elif Guzel9, Hafize Uzun10, Nermin Yelmen11, Gulderen Sahin12.
Abstract
Background and objectives: Ischemia-reperfusion (IR) caused by infrarenal abdominal aorta cross-clamping is an important factor in the development of ischemia-reperfusion injury in various distant organs. Materials andEntities:
Keywords: inflammation; ischemia–reperfusion; lung injury; oxidative stress; thymosin beta 4
Mesh:
Substances:
Year: 2019 PMID: 31121838 PMCID: PMC6572620 DOI: 10.3390/medicina55050187
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
The results of serum, bronchoalveolar lavage fluid (BALF), and lung tissue oxidative stress parameters in indicated groups.
| Groups | |||||
|---|---|---|---|---|---|
| Control | IR | Tβ4 + IR | I+Tβ4+R | ||
| Serum Oxidant /Anti-oxidant levels | LOOH (nmol/L) | 0.42 ± 0.02 | 0.30 ± 0.02 *** | 0.35 ± 0.01 ≠ | 0.32 ± 0.02 ≠≠≠ |
| MDA (µmol/mL) | 18.11 ± 0.72 | 8.49 ± 0.36 *** | 10.33 ± 1.01 ≠≠≠ | 8.84 ± 0.48 ≠≠≠ | |
| GSH † (µmol/g Hb) | 0.84 ± 0.01 | 1.19 ± 0.06 *** | 1.02 ± 0.06 ≠ | 1.07 ± 0.03 ≠≠≠ | |
| SOD (U/L) | 17.95 ± 1.50 | 10.81 ± 0.74 *** | 16.30 ± 0.70 ≠≠ | 17.42 ± 1.24 ≠≠ | |
| PAB (H2O2 %) | 24.37 ± 1.07 | 41.87 ± 2.37 *** | 26.58 ± 1.72 ≠≠≠ | 25.23 ± 2.24 ≠≠≠ | |
| FRAP (mmol uric acid) | 0.04 ± 0.00 | 0.08 ± 0.01 *** | 0.06 ± 0.01 ≠ | 0.07 ± 0.01 ≠≠ | |
| BALF Oxidant /Anti-oxidant levels | LOOH (nmol/L) | 4.08 ± 0.22 | 5.26 ± 0.13 *** | 4.30 ± 0.17 ≠≠ | 4.28 ± 0.14 ≠≠ |
| MDA (µmol/mL) | 13.76 ± 0.24 | 19.98 ± 1.53 *** | 14.59 ± 0.32 ≠≠≠ | 14.42 ± 0.36 ≠≠≠ | |
| GSH (µmol/L) | 0.69 ± 0.02 | 0.25 ± 0.02 *** | 0.60 ± 0.05 ≠≠≠ | 0.63 ± 0.02 ≠≠≠ | |
| SOD (U/L) | 19.50 ± 1.95 | 10.71 ± 0.86 *** | 16.84 ± 1.00 ≠ | 17.91 ± 1.03 ≠≠ | |
| PAB (H2O2 %) | 36.69 ± 0.82 | 43.34 ± 0.58 *** | 37.75 ± 1.30 ≠≠ | 37.49 ± 1.00 ≠≠ | |
| FRAP (mmol uric acid) | 0.06 ± 0.00 | 0.02 ± 0.01 *** | 0.04 ± 0.01 ≠ | 0.05 ± 0.01 ≠≠ | |
| Tissue Oxidant /Anti-oxidant levels | LOOH (nmol/wet tissue) | 3.59 ± 0.03 | 4.36 ± 0.05 *** | 3.76 ± 0.07 ≠≠≠ | 3.76 ± 0.02 ≠≠≠ |
| MDA (µmol/wet tissue) | 65.79 ± 0.68 | 84.09 ± 1.72 *** | 69.42 ± 1.09 ≠≠≠ | 69.54 ± 0.37 ≠≠≠ | |
| GSH (µmol/wet tissue) | 0.34 ± 0.03 | 0.17 ± 0.02 *** | 0.28 ± 0.02 ≠≠ | 0.30 ± 0.01 ≠≠≠ | |
| SOD (U/wet tissue) | 20.77 ± 1.62 | 13.39 ± 0.93 ** | 18.79 ± 1.28 ≠ | 20.64 ± 0.92 ≠≠ | |
| PAB (H2O2 % /wet tissue) | 113.40 ± 0.47 | 135.20± 2.33 *** | 120.60± 1.63 ≠≠≠ | 118.00± 2.39 ≠≠≠ | |
| FRAP (mmol uric acid /wet tissue) | 1.53 ± 0.03 | 1.01 ± 0.03 *** | 1.38 ± 0.01 ≠≠≠ | 1.45 ± 0.01 ≠≠≠ | |
LOOH: lipid hydroperoxide, MDA: malondialdehyde, PAB: pro-oxidant/anti-oxidant balance, Cu,Zn-SOD: superoxide dismutase, GSH: glutathione, FRAP: ferric reducing antioxidant power (** p < 0.01, *** p < 0.001 vs. control; ≠ p < 0.05, ≠≠ p < 0.01, ≠≠≠ p < 0.001 vs. IR). † Erythrocyte GSH levels.
The results of serum, BALF, and lung tissue pro-inflammatory cytokines and nuclear factor kappa B (NF-κB) in indicated groups.
| Groups | |||||
|---|---|---|---|---|---|
| Control | IR | Tβ4 + IR | I+Tβ4+R | ||
| Serum pro-inflammatory cytokines and NF-κB levels | TNF-α (pg/mL) | 45.36 ± 1.43 | 79.56 ± 3.18 *** | 50.46 ± 1.17 ≠≠≠ | 45.49 ± 1.14 ≠≠≠ |
| IL-6 (pg/mL) | 1517.00 ± 49.73 | 2448.00 ± 60.83 *** | 1561.00 ± 54.31 ≠≠≠ | 1555.00 ± 44.22 ≠≠≠ | |
| IL-1β (pg/mL) | 42.79 ± 3.19 | 81.82 ± 2.58 *** | 50.11 ± 3.32 ≠≠≠ | 46.32 ± 2.22 ≠≠≠ | |
| NF-κB (ng/mL) | 6.00 ± 0.52 | 12.05 ± 1.30 *** | 7.10 ± 0.25 ≠≠≠ | 6.74 ± 0.25 ≠≠≠ | |
| BALF pro-inflammatory cytokines and NF-κB levels | TNF-α (pg/mL) | 45.74 ± 1.63 | 78.58 ± 5.54 *** | 53.95 ± 2.77 ≠≠≠ | 51.35 ± 1.66 ≠≠≠ |
| IL-6 (pg/mL) | 1478.00 ± 52.67 | 2630.00 ± 71.86 *** | 1607.00 ± 70.06 ≠≠≠ | 1541.00 ± 47.37 ≠≠≠ | |
| IL-1β (pg/mL) | 233.90 ± 10.33 | 411.60 ± 27.90 *** | 247.00 ± 19.54 ≠≠≠ | 227.10 ± 11.80 ≠≠≠ | |
| NF-κB (ng/mL) | 9.63 ± 0.35 | 17.56 ± 1.88 *** | 10.25 ± 0.48 ≠≠≠ | 9.78 ± 0.45 ≠≠≠ | |
| Tissue pro-inflammatory cytokines and NF-κB levels | TNF-α (pg/100 µg protein) | 44.80 ± 1.01 | 72.32 ± 4.01 *** | 46.57 ± 1.02 ≠≠≠ | 42.59 ± 1.19 ≠≠≠ |
| IL-6 (pg/100 µg protein) | 109.30 ± 1.63 | 164.40 ± 3.07 *** | 117.60 ± 2.25 ≠≠≠ | 112.60 ± 1.94 ≠≠≠ | |
| IL-1β (pg/100 µg protein) | 130.50 ± 7.63 | 190.00 ± 7.14 *** | 152.20 ± 3.69 ≠≠ | 130.50 ± 7.81 ≠≠≠ | |
| NF-κB (ng/100 µg protein) | 1.00 ± 0.04 | 1.50 ± 0.06 *** | 1.17 ± 0.03 ≠≠≠ | 1.05 ± 0.06 ≠≠≠ | |
TNF-α: tumor necrosis factor alpha, IL-1β: Interleukin 1β, IL-6: Interleukin 6, NF-κB: nuclear factor-kappa B (*** p < 0.001 vs. control; ≠≠ p < 0.01, ≠≠≠ p < 0.001 vs. IR).
Figure 1Photomicrographs of lung samples and histological scoring of lung tissue. * p < 0.05, *** p < 0.001 vs. control; ≠≠≠ p < 0.001 vs. ischemia–reperfusion (IR). (A) Lung samples of the control group were stained with hematoxylin and eosin (H&E). The control group shows minimal negligible histological alterations in lung tissue. The alveolar walls are very thin, and the majority of the alveoli contain no cells; A: alveolus. (B) Representative photomicrographs of lung samples of the IR group stained with hematoxylin and eosin. The IR group shows moderate lung ischemia–reperfusion injury with marked blood vessel congestion (black arrow) and leukocytic infiltration of the alveolar lumen (red arrow); A: alveolus. (C) Representative photomicrographs of lung samples of thymosin beta 4 (Tβ4)/IR stained with hematoxylin and eosin. The image demonstrates the improvement of the lung histopathology regarding the lung ischemia–reperfusion injury. (D) Representative photomicrographs of lung samples of I/Tβ4/R stained with hematoxylin and eosin. The I/Tβ4/R group, similar to the Tβ4/IR group, has less damage than the IR group; red arrow: infiltrative cells in the lumen of the alveoli. (E) Histological scoring of lung tissue.